Pittsburgh experience with lower urinary tract botulinum toxin a injectionmichael B. ChancellorChristopher P. Smith Invited Commentary Pages: 235 - 236
α-Blockers in the management of acute urinary retention: Results of a double-blind, placebo-controlled study Kevin T. McVary Clinical Trials Report Pages: 241 - 242
Fact or fiction: What do the benign prostatic hyperplasia data tell us? Majid ShabbirRoger S. Kirby OriginalPaper Pages: 243 - 250
Symptom scores: Mumbo jumbo or meaningful measures? A. Christopher StageJohn C. Hairston OriginalPaper Pages: 251 - 256
Lasers for lower urinary tract symptoms secondary to benign prostatic hyperplasia: When is the fuss worth it? Werner W. HochreiterRoger M. Müller OriginalPaper Pages: 257 - 262
Acute urinary retention in men: the risks and outcomes with medical therapy Timothy B. HargreaveAlan S. McNeill OriginalPaper Pages: 263 - 270
Diagnosis and treatment of primary bladder neck obstruction in men Chad HuckabayVictor W. Nitti OriginalPaper Pages: 271 - 275
Granulomatous prostatitis linked to hla-drb1*1501 Robert F. Donnell Clinical Trials Report Pages: 279 - 279
Antinanobacterial therapy for men with chronic prostatitis/chronic pelvic pain syndrome and prostatic stones Robert F. Donnell Clinical Trials Report Pages: 279 - 280
Saw palmetto and finasteride in the treatment of category-iii prostatitis/chronic pelvic pain syndrome Jennifer YangAlexis E. Te OriginalPaper Pages: 290 - 295
Multimodal therapy for chronic prostatitis/chronic pelvic pain syndrome Daniel A. ShoskesErin Katz OriginalPaper Pages: 296 - 299
Role of bacteria in chronic prostatitis/ chronic pelvic pain syndrome Vi N. HuaDaniel H. WilliamsAnthony J. Schaeffer OriginalPaper Pages: 300 - 306
Prostatitis and serum prostate-specific antigen Puneet SindhwaniChristopher M. Wilson OriginalPaper Pages: 307 - 312
Therapeutic options for chronic prostatitis/chronic pelvic pain syndrome Jeannette M. Potts OriginalPaper Pages: 313 - 317
